Pharma BD Deal Intelligence
Eisai's up-to-$1.5B molecular glue bet on SEED Therapeutics is still just an option, not a commitment — SEED advanced its own RITE3 platform to a dosed Phase 1 patient in January 2026, but Eisai has yet to exercise rights on the undisclosed targets.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →SEED Therapeutics scored a $1.5 billion biobucks collaboration with Eisai, marking the biotech's second major pharma partnership following a 2022 deal with Eli…
Japan's Eisai said on Tuesday it has entered a strategic research collaboration with U.S. biotech SEED Therapeutics to discover novel molecular glue degraders…
Eisai is reaching beyond its Leqembi Alzheimer's franchise with a $1.5 billion molecular glue collaboration with SEED Therapeutics, including a Series…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
SEED Therapeutics entered strategic research collaboration with Eisai to discover molecular glue degraders for undisclosed neurodegeneration and oncology targets. SEED eligible for upfront plus preclinical, clinical, regulatory and sales milestones up to $1.5B plus tiered royalties. Also launched Series A-3 financing led by Eisai with $24M first close. Post-announcement, SEED completed the financing as a $30M Series A-3 ($24M first close Aug 2024 + $6M second close Aug 2025) and advanced its broader RITE3 molecular-glue platform: FDA cleared the IND for internal lead ST-01156 (RBM39 degrader) in Aug 2025 and the first Phase 1 patient (NCT07197554) was dosed Jan 2026. The Eisai collaboration remains a pending option-bearing research alliance — Eisai stays a cornerstone investor/collaborator and the $1.5B in biobucks is contingent on Eisai exercising exclusive rights on the undisclosed targets, which remain preclinical.
8M US cases/yr · $250.0B Combined US Oncology + Neurodegeneration Market (2024)
The Eisai-SEED Therapeutics collaboration targets undisclosed neurodegeneration and oncology targets using molecular glue degraders rather than a single indication. Neurodegenerative disorders including Alzheimer's disease (~6.7 million US patients), Parkinson's disease (~1 million), amyotrophic lateral sclerosis, and frontotemporal dementia collectively represent one of the fastest-growing therapeutic areas as populations age, driven by aggregation-prone proteins (amyloid-beta, tau, alpha-synuclein, TDP-43, huntingtin) historically considered undruggable by conventional small molecules. Oncology represents the largest therapeutic category globally with over 2 million new US cancer diagnoses annually, where transcription factors, scaffolding proteins, and mutant oncoproteins (KRAS, MYC, beta-catenin) have likewise resisted direct inhibition. Molecular glue degraders are small molecules that induce proximity between an E3 ubiquitin ligase (CRBN, DCAF15, DDB1-CUL4, RNF114) and a target protein, redirecting the ubiquitin-proteasome system to degrade otherwise undruggable proteins. The class is validated clinically by IMiDs (lenalidomide, pomalidomide, iberdomide) and by the emergence of targeted CELMoDs, positioning molecular glues as a preferred modality for high-value CNS and oncology targets where catalytic degradation offers advantages over occupancy-based inhibition.
The molecular glue and targeted protein degradation competitive landscape has rapidly expanded across approved drugs and discovery platforms. IMiD/CELMoD molecular glues from Bristol Myers Squibb include Revlimid (lenalidomide), Pomalyst (pomalidomide), Thalomid (thalidomide), Iberdomide (CC-220), and Mezigdomide (CC-92480) anchoring the commercial proof-of-concept for CRBN-mediated degradation. Competing molecular glue platforms include Monte Rosa Therapeutics (QuEEN platform, MRT-2359 GSPT1 degrader, Novartis partnership), C4 Therapeutics (CFT1946 BRAF V600E, CFT8634 BRD9, Roche partnership), Kymera Therapeutics (KT-474 IRAK4 Sanofi-partnered, KT-253 MDM2, KT-621 STAT6 Sanofi-partnered), Arvinas (ARV-471/vepdegestrant ER Pfizer-partnered, ARV-766 AR), Foghorn Therapeutics (Eli Lilly partnership), Neomorph (Novo Nordisk and Biogen partnerships), Nurix Therapeutics (NX-5948 BTK and NX-2127 BTK/IKZF Gilead/Sanofi), Plexium, Captor Therapeutics, Orum Therapeutics, Proxygen (Boehringer partnership), Vividion (Bayer/Roivant), and Biotheryx. Eisai's own neurodegeneration franchise includes Leqembi (lecanemab anti-amyloid antibody with Biogen) and pipeline tau antibody E2814, contextualizing the strategic rationale for SEED's CNS-focused molecular glue discovery. SEED's RITE3 rational-design platform differentiates through structure-based engineering rather than phenotypic screens.
FDA cleared SEED Therapeutics' IND for ST-01156, a brain-penetrant molecular glue degrader of RBM39, enabling a first-in-human Phase 1 (NCT07197554) in advanced solid tumors / hematologic malignancies. Orphan Drug and Rare Pediatric Disease designations granted for Ewing sarcoma. Validates the molecular-glue platform underlying the Eisai collaboration, though ST-01156 is SEED's internal asset, not an Eisai-partnered target.
SEED Therapeutics closed its $30M Series A-3 financing: $24M first close (Aug 2024, led by Eisai) plus a $6M second close (Aug 2025). SEED reports ~$60M total equity plus collaboration upfront/milestone payments combined from its Eli Lilly and Eisai partnerships.
SEED Therapeutics dosed the first patient in the Phase 1 trial of ST-01156 (NCT07197554), a molecular glue degrader of RBM39, on Jan 9, 2026, marking its transition to a clinical-stage company. Eisai cited as cornerstone investor and research collaborator. The Eisai-partnered undisclosed neurodegeneration/oncology targets remain preclinical with options unexercised.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eisai Co., Ltd. / SEED Therapeutics Inc. (this deal) | 2024 | $1.5B | — |
| Eisai Co., Ltd. / Ligand Pharmaceuticals (oncology product portfolio) | 2006 | $205M | 41 |
| Eisai Co., Ltd. / MGI Pharma Inc. | 2007 | $3.9B | 36 |
| Eisai Co., Ltd. / Henlius | 2026 | — | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
← Browse all deals · How we score deals
More: 2024 deals · Eisai Co., Ltd. deals · Neurology deals